Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3weeks in solid tumours: An ECSG/EORTC study
- 31 March 2005
- journal article
- clinical trial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 41 (5), 702-707
- https://doi.org/10.1016/j.ejca.2004.12.023
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cellsEuropean Journal of Pharmacology, 2001
- Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS 828. Comparison with methylglyoxal-bis(guanylhydrazone)European Journal of Pharmacology, 2001
- Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in ratsCancer Chemotherapy and Pharmacology, 2000
- Novel cyanoguanidines with potent oral antitumour activityBioorganic & Medicinal Chemistry Letters, 1997